Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Under The Radar: Bankruptcy News You May Have Missed No Photo Available

Emlyn Cameron

A bankruptcy judge approved Village Roadshow's proposal to pay a handful of important employees bonuses to stick around. A brokerage i... (more story)

Top Federal Tax Cases Of 2025: Midyear Report No Photo Available

Anna Scott Farrell

In the first half of the year, the U.S. Supreme Court barred a defunct transportation company's bankruptcy trustee from clawing back f... (more story)

Bankruptcy Motion Marks Rising Salience Of Cyber Coverage No Photo Available

Abraham Gross

Unprecedented arguments in a data company's bankruptcy petition that cite a failure to maintain adequate cyberinsurance coverage under... (more story)